This article is more than 5 years old. Information may no longer be current.
RecQ1 A159C genotype predictive for some resectable pancreatic cancers
Click Here to Manage Email Alerts
Researchers said they have confirmed that the DNA repair gene RecQ1 A159C variant is a prognostic or predictive factor for patients with resectable pancreatic cancer who have undergone preoperative chemoradiation.
Donghui Li, PhD, said RecQ1 variant AC/CC genotype carriers were more likely to die of their disease than carriers of the AA genotype.
“We observed a significant association of this genotype with OS,” she said. “Median survival time was shorter for the AC/CC carriers compared with the AC carriers.”
Li, a professor in the department of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, presented the results during the 2011 Gastrointestinal Cancers Symposium in San Francisco.
Researchers assessed DNA of 154 patients enrolled in RTOG-9704, a phase 3 study of adjuvant pre- and post-chemoradiation with 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma, for the RecQ1 genotype. Researchers then used a multivariate Cox proportional hazards model to determine whether there was a correlation between genotype and OS.
Twenty percent of patients had the CC genotype, 43% had AC and 37% had AA. Li said patients with the RecQ1 variant AC/CC genotype were more likely to be node-positive (P=.03).
Median OS was 1.72 years for AA carriers (95% CI, 1.36-2.17), 1.57 years for AC (95% CI, 1.18-1.80) and 1.18 years for CC (95% CI, 0.86-1.75).
OS was 1.4 years in the combined AA/CC group
“The hazard ratio was 1.52, even after adjusting for treatment arm, age, gender, race, nodal involvement, tumor diameter and surgical margin status,” Li said. “That indicates that this genotype is an independent predictor for survival.”
Multivariate analysis showed that the risk for death was greater among patients with the AC/CC genotypes compared with the AA genotype (HR=1.54; 95% CI, 1.07-2.23). Li said the effect was more pronounced for the 82 patients assigned 5-FU (HR=1.64; 95% CI, 0.99-2.70) than for the 72 patients assigned gemcitabine (HR=1.46; 95% CI, 0.81-2.63).
She said more research is needed to determine whether the association between genotype and outcome exists in patients treated with gemcitabine.
For more information:
- Li D. #156. Presented at: the 2011 Gastrointestinal Cancers Symposium; Jan. 20-22, 2011; San Francisco.
Disclosure: Dr. Li reports no relevant financial disclosures.